Notably, many reported cases of lineage switch in B-ALL occurred either during or shortly after induction therapy, particularly in patients receiving CD19-directed immunotherapies such as blinatumomab or CD19 CAR T-cell therapy [4, 14]. Here, CD19 is linked to acute lymphoblastic leukemia.